Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124110 | 1.00 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| SCHEMBL5123437 | 1.00 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| SCHEMBL5124757 | 1.00 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| SCHEMBL5123449 | 1.00 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| Hydrochloric Acid SCHEMBL5117576 | 0.99 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| Bromide SCHEMBL5123871 | 0.99 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| SCHEMBL5117048 | 0.99 | CYP2C19 (0.43) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| Hydrochloric Acid SCHEMBL5125644 | 0.99 | CYP2C19 (0.43) | CYP2C19SMN1; SMN2TSHRATMCACNA1B | |
| SCHEMBL5110234 | 0.94 | CTSL (0.40) | CYP2C19SMN1; SMN2ATMCACNA1BHSD17B10 | |
| SCHEMBL5123989 | 0.94 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2TSHRDPP7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | claimed |
| EP-1829549-A1 | AMORPHOUS COMPOSITION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20040067891-A1 | Therapeutic and/or preventive agents for diseases due to retinal ischemia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | claimed |
| EP-1356817-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR DISEASES DUE TO RETINAL ISCHEMIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | claimed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | claimed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | claimed |
| US-20090292021-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC (FR) | 2009-11-26 | — | — | US | disclosed |
| EP-2046320-A2 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (Institut National de la Santé et de la Recherche Medicale) (FR) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| WO-2008015202-A2 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-02-07 | — | — | WO | disclosed |
| US-20040067891-A1 | Therapeutic and/or preventive agents for diseases due to retinal ischemia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040067891-A1 | Therapeutic and/or preventive agents for diseases due to retinal ischemia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
| EP-1356817-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR DISEASES DUE TO RETINAL ISCHEMIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1356817-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR DISEASES DUE TO RETINAL ISCHEMIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096924-A1 | Amorphous Composition | CACNA1B, CACNA1I, TRPV1 | CYP2C19 1197/4885SMN1; SMN2 814/4885TSHR 4272/4885 |
| US-20040067891-A1 | Therapeutic and/or preventive agents for diseases due to retinal ischemia | ALDH1A2, RBP4, GPR119 | CYP2C19 4841/4885SMN1; SMN2 1712/4885TSHR 2097/4885 |
| US-20090292021-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | GABRE, GABRP, GABRB2 | CYP2C19 597/4885SMN1; SMN2 769/4885TSHR 4741/4885 |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | CYP2C19 3106/4885SMN1; SMN2 172/4885TSHR 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.